Recent

% | $
Quotes you view appear here for quick access.

Enterprise Products Partners L.P. Message Board

jad9000 353 posts  |  Last Activity: 1 hour 31 minutes ago Member since: Nov 3, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    One thing that everyone knows...

    by biowatchdog Aug 27, 2015 1:15 PM
    jad9000 jad9000 1 hour 31 minutes ago Flag

    Terry stated "he's out" just before Insmed took off and rallied big, with more to come. Now he claims to have had 13,000 shares - more like zero. He has no ability to respond to any educated statements as he is an illiterate moron. He makes idiotic statements and when he gets called on them he deletes own posts. He has a long history of claiming everyone is wrong but him, that he never lost a dime on any trade he's made, that Iplex is dead (witness testing still ongoing for various uses as of this month) and the list goes on. Terry has, as far as can be figured out, at least 35 fake ids that he uses to praise himself and thumbs down and attack anyone who disagrees or calls him out. He claims he is a California surfer "dude" but posts at all kinds of odd hours that are completely inconsistent with the west coast time zone. Finally, every once in a while he gets pretty drunk on a weekend and really starts spouting complete gibberish in pigeon English with second grade grammar and third grade spelling. Aren't we lucky that he decided to bless this board - not.

    Sentiment: Strong Buy

  • jad9000 jad9000 1 hour 36 minutes ago Flag

    Great info from Biowatchdog: From EPUB July 27, 2015
    “In 2010, we estimated 86,244 national cases, totaling to $815 million, of which 87% were inpatient- ($709 million) and 13% outpatient-related ($106 million). Annual state estimates varied from 48 to 12,544 cases ($503k-$111 million), with a median of 1,208 cases ($11.5 million). Oceanic coastline and Gulf States comprised 70% of NTM cases, yet 60% of the US population. Medical encounters among individuals ≥65 ($562 million) were two-fold higher than those aged below.

    Sentiment: Strong Buy

  • Reply to

    Have to admit, Terry is completely nuts

    by jad9000 Aug 18, 2015 11:18 AM
    jad9000 jad9000 1 hour 43 minutes ago Flag

    Terry the freak continues to delete and repost - and claim someone else is doing it.
    The resident freak is back posting gibberish yet again. Bash, insult, praise himself, delete posts, repost, bash, insult, praise himself,, delete posts, repost, bash, insult, praise himself, delete posts, repost, bash, insult, praise himself, delete posts, repost, bash, insult, praise himself, delete posts, repost, bash, insult , praise himself - and on, and on, and on.......... What a complete freak this clown is.

    Sentiment: Strong Buy

  • Reply to

    Terry's Recent Disappointment

    by jad9000 Aug 29, 2015 12:59 PM
    jad9000 jad9000 Aug 29, 2015 2:08 PM Flag

    Someone go get Terry's straight jacket. He escaped from it this morning.

    Sentiment: Strong Buy

  • jad9000 jad9000 Aug 29, 2015 2:04 PM Flag

    Revenue in 2015 when the liar Terry has said as far out as 2017. What a goofball.

    Sentiment: Strong Buy

  • Reply to

    Have to admit, Terry is completely nuts

    by jad9000 Aug 18, 2015 11:18 AM
    jad9000 jad9000 Aug 29, 2015 1:57 PM Flag

    Terry the freak continues to delete and repost - and claim someone else is doing it.
    The resident freak is back posting gibberish yet again. Bash, insult, praise himself, delete posts, repost, bash, insult, praise himself,, delete posts, repost, bash, insult, praise himself, delete posts, repost, bash, insult, praise himself, delete posts, repost, bash, insult, praise himself, delete posts, repost, bash, insult , praise himself - and on, and on, and on.......... What a complete freak this clown is.

    Sentiment: Strong Buy

  • jad9000 jad9000 Aug 29, 2015 1:07 PM Flag

    Thx to Biowatchdog:
    On EPUB (ahead of print) July 27, 2015
    “In 2010, we estimated 86,244 national cases, totaling to $815 million, of which 87% were inpatient- ($709 million) and 13% outpatient-related ($106 million). Annual state estimates varied from 48 to 12,544 cases ($503k-$111 million), with a median of 1,208 cases ($11.5 million). Oceanic coastline and Gulf States comprised 70% of NTM cases, yet 60% of the US population. Medical encounters among individuals ≥65 ($562 million) were two-fold higher than those aged below.

    Sentiment: Strong Buy

  • He's been certified as a lunatic liar.

    Sentiment: Strong Buy

  • Reply to

    One thing that everyone knows...

    by biowatchdog Aug 27, 2015 1:15 PM
    jad9000 jad9000 Aug 29, 2015 11:32 AM Flag

    Repost from gt_pharma

    Troll Terry hates facts..

    Sentiment: Strong Buy

  • Reply to

    Have to admit, Terry is completely nuts

    by jad9000 Aug 18, 2015 11:18 AM
    jad9000 jad9000 Aug 29, 2015 11:24 AM Flag

    The resident freak is back posting gibberish yet again. Bash, insult, praise himself, delete posts, repost, bash, insult, praise himself,, delete posts, repost, bash, insult, praise himself, delete posts, repost, bash, insult, praise himself, delete posts, repost, bash, insult, praise himself, delete posts, repost, bash, insult , praise himself - and on, and on, and on.......... What a complete freak this clown is.

    Sentiment: Strong Buy

  • Reply to

    One thing that everyone knows...

    by biowatchdog Aug 27, 2015 1:15 PM
    jad9000 jad9000 Aug 29, 2015 11:17 AM Flag

    To the top from Biowatchdog
    Terry_insmed{a.k.a. virtually every other id posting on here} is using no information and hoping to get an emotional response. Every day he does exactly the same thing posting unfounded, inane comments and his alter-ego clowns one after another, who know nothing about the approval process, chimes in to echo the unfounded opinion and incomprehensible posts; such as “In fact, the company was pushed back as the clock stopped for questions at day 120.” This example left readers wondering how the heck the company was pushed back.
    Now we have terry_insmed bashing the reference of a very recent abstract from experts on the prevalence of NTM in the U.S. and its costs as irrelevant non-information and pretending to have a handle on everything that these experts do not even know. Even using the “abstract” (in quotes) to connote unscientific research.

    Insmed plans for a limited launch in mid late 2016 in a couple of countries in Europe where NTM is most prevalent and gradually elsewhere taking what they learn to plan the eventual launch in the Unit States. The EMA will follow their process within the timing outlined in their guidelines. If you are dumb enough to fall for terry’s latest distraction then you are in big doo-doo as nobody has been gullible enough to fall for this garbage, let understand it for a decade.
    Yes, PT Barnum nailed it, but Terry never read it… “Unless a man enters upon the vocation intended for him by nature, and best suited to his peculiar genius, he cannot succeed.”

    Sentiment: Strong Buy

  • jad9000 jad9000 Aug 28, 2015 8:27 PM Flag

    It is so much revenue that I can't fathom it. Remember, the EU has about half the number of US cases as does Japan. So, double your number. But, as we don't see analysts crawling on top of each other to upgrade we must be missing something.

    Sentiment: Strong Buy

  • Reply to

    One thing that everyone knows...

    by biowatchdog Aug 27, 2015 1:15 PM
    jad9000 jad9000 Aug 28, 2015 1:34 PM Flag

    From Biowatchdog
    Terry_insmed{a.k.a. virtually every other id posting on here} is using no information and hoping to get an emotional response. Every day he does exactly the same thing posting unfounded, inane comments and his alter-ego clowns one after another, who know nothing about the approval process, chimes in to echo the unfounded opinion and incomprehensible posts; such as “In fact, the company was pushed back as the clock stopped for questions at day 120.” This example left readers wondering how the heck the company was pushed back.
    Now we have terry_insmed bashing the reference of a very recent abstract from experts on the prevalence of NTM in the U.S. and its costs as irrelevant non-information and pretending to have a handle on everything that these experts do not even know. Even using the “abstract” (in quotes) to connote unscientific research.

    Insmed plans for a limited launch in mid late 2016 in a couple of countries in Europe where NTM is most prevalent and gradually elsewhere taking what they learn to plan the eventual launch in the Unit States. The EMA will follow their process within the timing outlined in their guidelines. If you are dumb enough to fall for terry’s latest distraction then you are in big doo-doo as nobody has been gullible enough to fall for this garbage, let understand it for a decade.
    Yes, PT Barnum nailed it, but Terry never read it… “Unless a man enters upon the vocation intended for him by nature, and best suited to his peculiar genius, he cannot succeed.”

    Sentiment: Strong Buy

  • Reply to

    Terry Please Repost

    by tycint Aug 16, 2015 3:09 PM
    jad9000 jad9000 Aug 28, 2015 1:29 PM Flag

    Just keep topping Terry.
    Terry the freak liar has no ability to respond to any educated statements as he is an illiterate moron. He makes idiotic statements and when he gets called on them he deletes own posts. He has a long history of claiming everyone is wrong but him, that he never lost a dime on any trade he's made, that Iplex is dead (witness testing still ongoing for various uses as of this month) and the list goes on. Terry has, as far as can be figured out, at least 35 fake ids that he uses to praise himself and thumbs down and attack anyone who disagrees or calls him out. He claims he is a California surfer "dude" but posts at all kinds of odd hours that are completely inconsistent with the west coast time zone. Finally, every once in a while he gets pretty drunk on a weekend and really starts spouting complete gibberish in pigeon English with second grade grammar and third grade spelling. Aren't we lucky that he decided to bless this board - not.

    Sentiment: Strong Buy

  • Reply to

    Way more money with NTM at higher prices

    by jad9000 Aug 28, 2015 8:48 AM
    jad9000 jad9000 Aug 28, 2015 10:52 AM Flag

    To the top
    Now we know that they will make way more money with NTM priced much higher. And, Arikace cures MAC and other diseases in CF patients. CF would have been a huge drag on sales revenue and profits, Good that they pushed it to the background.

    - Number of CF patients equals roughly 80% of NTM patients.
    - Number of CF patients who also suffer from NTM is roughly 20%.
    - Number of competing drugs for CF is four to five
    - Duration of CF treatment days indicated by Insmed is six months per year - quarter on, quarter off
    So we have 80% of the NTM market, of which we get 20% automatically through NTM use
    We get possibly 1/4 of the remaining due to competition
    The estimated price for CF was around $45,000 but due to the on/off regimen only $22,500 per year.
    On the basis of 100,000 CF patients we get:
    $22,500 x 80% of market (Non-NTM population) x 25% (the rest to competitors) x 100,000 = $450 million
    On the basis of 100,000 NTM patients - including 20,000 CF afflicted we get:
    20,000 x $60,000 = $1.2 billion for CF afflicted
    80,000 x $60,000 = $4.8 billion for the rest
    The incremental revenue generated over CF pricing is $15,000 x 100,000, or $1.5 billion plus the same $450 million we would generate through CF sales.
    So, by not selling at lower prices to CF patients, and not also bearing the cost of sales and marketing, we generate in total incremental revenue of $1.95 billion plus millions in savings.

    Sentiment: Strong Buy

  • Reply to

    EMA Approval Prospects

    by tycint Aug 13, 2015 7:43 PM
    jad9000 jad9000 Aug 28, 2015 10:09 AM Flag

    Terry/teetertotter44 is back and talking nonsense again. Here's the label our resident goofball and pathological liar Terry/teetertotter44 and his refractory nonsense seems to think the EMA will allow them - "Prescribe only when patient is in hospice or has been given last rites". I wish I was a class action lawyer if Terry has his way. Think about the 110,000 suffering patients that wouldn't be close enough to death's door to qualify for Arikace at just how much they would sue for. And imagine if an insurance company tried to not reimburse. And, finally, imagine how much Insmed could increase the price to then.

    Sentiment: Strong Buy

  • Reply to

    Have to admit, Terry is completely nuts

    by jad9000 Aug 18, 2015 11:18 AM
    jad9000 jad9000 Aug 28, 2015 10:02 AM Flag

    Repost:
    It appears that Terry let teetertotter44 out of the closet now too. He has clearly lost control of his fake ids who are now running amok on the board. I will add all the new fakes to the list and repost them for all to see - what a complete freak we have on the board. That would be Terry the schizo.

    Sentiment: Strong Buy

  • Reply to

    FDA NTM meeting

    by checksurshorts Jul 25, 2015 12:46 PM
    jad9000 jad9000 Aug 28, 2015 9:16 AM Flag

    And growing at 12% annually as well. Apparently, given the diagnostic issues and subsequent under identification, we have no idea now just how big this market actually is both in the US and globally.

    Sentiment: Strong Buy

  • Now we know that they will make way more money with NTM priced much higher. And, Arikace cures MAC and other diseases in CF patients. CF would have been a huge drag on sales revenue and profits, Good that they pushed it to the background.

    - Number of CF patients equals roughly 80% of NTM patients.
    - Number of CF patients who also suffer from NTM is roughly 20%.
    - Number of competing drugs for CF is four to five
    - Duration of CF treatment days indicated by Insmed is six months per year - quarter on, quarter off
    So we have 80% of the NTM market, of which we get 20% automatically through NTM use
    We get possibly 1/4 of the remaining due to competition
    The estimated price for CF was around $45,000 but due to the on/off regimen only $22,500 per year.
    On the basis of 100,000 CF patients we get:
    $22,500 x 80% of market (Non-NTM population) x 25% (the rest to competitors) x 100,000 = $450 million
    On the basis of 100,000 NTM patients - including 20,000 CF afflicted we get:
    20,000 x $60,000 = $1.2 billion for CF afflicted
    80,000 x $60,000 = $4.8 billion for the rest
    The incremental revenue generated over CF pricing is $15,000 x 100,000, or $1.5 billion plus the same $450 million we would generate through CF sales.
    So, by not selling at lower prices to CF patients, and not also bearing the cost of sales and marketing, we generate in total incremental revenue of $1.95 billion plus millions in savings.

    Sentiment: Strong Buy

  • jad9000 jad9000 Aug 28, 2015 8:31 AM Flag

    Back to the top:
    On EPUB (ahead of print), Jul 27, 2015

    “In 2010, we estimated 86,244 national cases, totaling to $815 million, of which 87% were inpatient- ($709 million) and 13% outpatient-related ($106 million). Annual state estimates varied from 48 to 12,544 cases ($503k-$111 million), with a median of 1,208 cases ($11.5 million). Oceanic coastline and Gulf States comprised 70% of NTM cases, yet 60% of the US population. Medical encounters among individuals ≥65 ($562 million) were two-fold higher than those aged

    Sentiment: Strong Buy

EPD
28.62+0.16(+0.56%)Aug 28 4:02 PMEDT